Table 1.

Age and marker values for the 757 participants in the study

Participant characteristics (n = 757)Healthy control (n = 177)Benign disease (n = 399)Ovarian cancer total (n = 181)Ovarian cancer (n = 181), International Federation of Gynecology and Obstetrics stage
I (n = 45)II (n = 17)III (n = 101)IV (n = 18)
Age, median (range),* y37 (21-79)44 (18-85)62 (20-88)56 (20-83)64 (44-76)62 (22-88)61 (26-76)
Afamin, median (10th, 90th percentile) (range), mg/L70.7 (52.6-90.9) (29.9-116.1)65.1 (49.1-90.4) (20.2-206.6)56.0 (29.7-78.5) (4.7-96.0)58.1 (39.5-81.5) (27.6-96.0)56.0 (35.9-81.0) (8.9-90.3)53.7 (27.1-77.6) (4.7-87.8)63.8 (28.2-76.6) (12.7-88.3)
apoA-IV, median (10th, 90th percentile) (range),,,§ mg/dL13.0 (8.3-19.6) (5.5-34.0)11.7 (6.5-18.5) (2.0-32.3)9.3 (4.8-16.3) (0.3-29.5)11.4 (4.9-18.5) (2.6-29.5)8.9 (4.8-15.7) (4.0-29.5)8.6 (4.6-14.8) (0.3-24.0)9.9 (4.9-16.2) (2.8-18.2)
CA125, median (10th, 90th percentile) (range),,, units/mL12.9 (7.6-23.9) (3.2-68.8)17 (8.1-81.2) (3.3-1,026.0)290 (26.7-2,860) (10.3-27,070)36.6 (15.1-225.5) (10.3-1,370.0)435.0 (67.5-2,320.6) (35.9-4,380.0)501.0 (102.0-3,166.0) (24.2-27,070.0)442.0 (30.6-1,671.2) (10.4-7,307.0)
  • * P < 0.0001, based on differences between healthy controls, benign cases, and ovarian cancer patients (ANOVA).

  • P < 0.1 for difference between stages I and II and III and IV.

  • P < 0.05 for difference between stages I and II and III and IV.

  • § P < 0.1 for difference among all stages (ANOVA).

  • P < 0.001 for difference between stages I and II and III and IV.

  • P < 0.05 for difference among all stages (ANOVA).